<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Oncotarget</journal-id>
<journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id>
<journal-id journal-id-type="publisher-id">Oncotarget</journal-id>
<journal-id journal-id-type="publisher-id">ImpactJ</journal-id>
<journal-title-group>
<journal-title>Oncotarget</journal-title>
</journal-title-group>
<issn pub-type="epub">1949-2553</issn>
<publisher>
<publisher-name>Impact Journals LLC</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29568349</article-id>
<article-id pub-id-type="pmc">5862570</article-id>
<article-id pub-id-type="publisher-id">23719</article-id>
<article-id pub-id-type="doi">10.18632/oncotarget.23719</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Paper</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Exploring the pathogenesis of canine epilepsy using a systems genetics method and implications for anti-epilepsy drug discovery</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Cui</surname>
<given-names>Ze-Jia</given-names>
</name>
<xref ref-type="aff" rid="A1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Ye-Mao</given-names>
</name>
<xref ref-type="aff" rid="A1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Qiang</given-names>
</name>
<xref ref-type="aff" rid="A1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xia</surname>
<given-names>Jingbo</given-names>
</name>
<xref ref-type="aff" rid="A1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Hong-Yu</given-names>
</name>
<xref ref-type="aff" rid="A1">
<sup>1</sup>
</xref>
</contrib>
<aff id="A1"><sup>1</sup> Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Hubei, Wuhan, China</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><bold>Correspondence to:</bold> Jingbo Xia, <email>xiajingbo.math@gmail.com</email></corresp>
<fn fn-type="equal" id="FN1">
<label>*</label>
<p>These authors contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<day>2</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>27</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>9</volume>
<issue>17</issue>
<fpage>13181</fpage>
<lpage>13192</lpage>
<history>
<date date-type="received">
<day>5</day>
<month>7</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>11</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © 2018 Cui et al.</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</ext-link> 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<abstract>
<p>Epilepsy is a common neurological disorder in domestic dogs. However, its complex mechanism involves multiple genetic and environmental factors that make it challenging to identify the real pathogenic factors contributing to epilepsy, particularly for idiopathic epilepsy. Conventional genome-wide association studies (GWASs) can detect various genes associated with epilepsy, although they primarily detect the effects of single-site mutations in epilepsy while ignoring their interactions. In this study, we used a systems genetics method combining both GWAS and gene interactions and obtained 26 significantly mutated subnetworks. Among these subnetworks, seven genes were reported to be involved in neurological disorders. Combined with gene ontology enrichment analysis, we focused on 4 subnetworks that included traditional GWAS-neglected genes. Moreover, we performed a drug enrichment analysis for each subnetwork and identified significantly enriched candidate anti-epilepsy drugs using a hypergeometric test. We discovered 22 potential drug combinations that induced possible synergistic effects for epilepsy treatment, and one of these drug combinations has been confirmed in the Drug Combination database (DCDB) to have beneficial anti-epileptic effects. The method proposed in this study provides deep insight into the pathogenesis of canine epilepsy and implications for anti-epilepsy drug discovery.</p>
</abstract>
<kwd-group>
<kwd>canine</kwd>
<kwd>systems genetics</kwd>
<kwd>pathogenic factors</kwd>
<kwd>drug combinations</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>INTRODUCTION</title>
<p>Epilepsy is a common serious neurological disease, which does latent harm to human health [<xref ref-type="bibr" rid="R1">1</xref>]. Treatments of epilepsy are currently limited to drugs that provide only symptomatic control of seizures. Current treatments have adverse effects and are ineffective in up to 40% of patients [<xref ref-type="bibr" rid="R2">2</xref>]. However, the pathogenesis of epilepsy, and the resistance to available antiepileptic drugs remains poorly understood [<xref ref-type="bibr" rid="R1">1</xref>]. Though a better understanding of the genetic targets and mechanisms of anti-seizure drug activity offers trusty direction in drug selection for individual patients, the experiments in need are ethically and technically difficult. For this reason, animal models are useful in anti-seizure drug research [<xref ref-type="bibr" rid="R3">3</xref>]. One such model organism is the dog, because both humans and companion animals suffer from epilepsy, which is a chronic neurologic disorder affecting nearly 50 million people and 0.5–5% of the canine population worldwide [<xref ref-type="bibr" rid="R4">4</xref>]. Conversely, models of anti-seizure medication targets and activities that are derived from humans are useful in epilepsy research in a canine context.</p>
<p>Domestic dogs share many parallel syndromes with humans [<xref ref-type="bibr" rid="R4">4</xref>]. Evolutionarily speaking, similarities in medical genetics between dogs and humans can be found throughout history. Dogs evolved from the gray wolf in East Asia at least 15,000 years ago, co-operationally integrated with mankind, and developed a mutually beneficial relationship over a long period of time. Many dog breeds have shown a high prevalence of specific diseases, such as blindness, cancer, heart disease, and epilepsy [<xref ref-type="bibr" rid="R5">5</xref>], most of which are also common in humans. Furthermore, the clinical manifestations of the two species are often similar [<xref ref-type="bibr" rid="R6">6</xref>]. High-quality draft genome sequencing, has verified a degree of similarity of 96% between dog and human genes [<xref ref-type="bibr" rid="R7">7</xref>]. Therefore, the domestic dog is treated as a valuable model species for human diseases [<xref ref-type="bibr" rid="R4">4</xref>], and canine epilepsy pathogenesis is regarded as the same as that of human epilepsy. Thus, human anti-epilepsy drugs are promising agents for canine therapy.</p>
<p>Even prior to the problems of selection of anti-seizure medications, diagnosis of epilepsy is complicated. Generally, at least two unprovoked seizures, or one seizure combined with additional symptoms, e.g., adverse head injury, previous stroke or an abnormality on an electroencephalogram (EEG) brain scan, are required for diagnosis [<xref ref-type="bibr" rid="R8">8</xref>]. However, it is more difficult than that in some cases, the cause of most cases of epilepsy is unknown [<xref ref-type="bibr" rid="R9">9</xref>]. Generally speaking, canine epilepsy can be divided into reactive seizures, structural epilepsy, and idiopathic epilepsy according to etiology [<xref ref-type="bibr" rid="R10">10</xref>]. The mechanism of reactive seizures is the response of the brain to abnormal systemic metabolism, such as hypoglycemia, hypocalcemia, uremia, poisoning and so on. Structural epilepsy is mainly due to abnormal brain structure, including brain abnormalities caused by hydrocephalus, craniocerebral tumor causing compression of brain parenchyma, trauma caused by brain injury or damage, infectious diseases such as toxoplasmosis, rabies, tetanus and other pathogens into the brain tissue, or destruction of the normal structure of brain tissue. Idiopathic epilepsy or primarily genetic epilepsy, which is associated with congenital or genetic factors, is the most common neurological disorder in dogs [<xref ref-type="bibr" rid="R11">11</xref>]. However, the mechanism of idiopathic epilepsy remains unclear.</p>
<p>Anti-epileptic drugs (AEDs) have long been administered to humans and dogs. Early in 1857, bromide was introduced to treat epilepsy [<xref ref-type="bibr" rid="R12">12</xref>]. It was combined with potassium or sodium to form a crystal powder. Currently, there are over 20 anti-epileptic drugs on the market for treating humans. These include carbamazepine (also known as carbatrol, equetro, tegretol), gabapentin (neurontin), levetiracetam (keppra), lamotrigine (lamictal), oxcarbazepine (trileptal), pregabalin (lyrica), tiagabine (gabitril), topiramate (topamax), and valproate (depakote, depakene). The first three types of drugs are also widely used in dogs. Furthermore, there are also AEDs for dogs, such as clorazepate, diazepam, felbamate, phenobarbital, phenytoin, primidone, valproic acid, and zonisamide (<ext-link ext-link-type="uri" xlink:href="http://www.canine-epilepsy.com/AEDs.html">http://www.canine-epilepsy.com/AEDs.html</ext-link>). Though many new drugs have been developed that work well in humans, their efficacies decrease in canine treatment because dogs metabolize these drugs much more quickly, making new drug discovery for dogs challenging.</p>
<p>The recent availability of a large number of canine genetic samples presents an opportunity to realize the promise of using understanding of the genetic targets and mechanisms of anti-seizure drug activity to help in drug selection for individual patients. A promising approach to finding these genetic things is the Genome-Wide Association Study (GWAS) [<xref ref-type="bibr" rid="R13">13</xref>]. The first GWAS on focal epilepsy was carried out with 3,445 patients and 6,935 controls from Northern Europe. No significant genetic markers were found, as none of the single nucleotide polymorphisms (SNPs) corresponded to <italic>P</italic>-values that reached significance after Bonferroni correction [<xref ref-type="bibr" rid="R14">14</xref>]. Flank expansion of 95 and 116 kb from the top SNP only led to a predicted pseudogene. A second GWAS study on 1,000 patients from China identified two highly correlated variants in CAMSAP1L1 (CAMSAP1-Like 1), a calmodulin-regulated spectrin-associated protein expressed in neurons and astrocytes in the mammalian nervous system [<xref ref-type="bibr" rid="R15">15</xref>]. Although each GWAS study thus far has offered a list of candidate genes, few of these genes have been functionally validated. For most patients, epilepsy is regarded as a complex disorder associated with multiple genes and external environmental factors, which also makes it difficult to rely on single-gene associations. Therefore, it is hoped that earlier findings can be enhanced by additional GWAS results and next-generation DNA sequencing (NGS) [<xref ref-type="bibr" rid="R16">16</xref>].</p>
<p>Prior to the GWAS, 10 genes had been reported as underlying canine epilepsy [<xref ref-type="bibr" rid="R4">4</xref>]. Among these, 9 genes are associated with progressive myoclonic epilepsy in several dog breeds, i.e., <italic>EPM2B</italic> [<xref ref-type="bibr" rid="R17">17</xref>], <italic>CLN8</italic> [<xref ref-type="bibr" rid="R18">18</xref>], <italic>CLN5</italic> [<xref ref-type="bibr" rid="R19">19</xref>], <italic>CTSD</italic> [<xref ref-type="bibr" rid="R20">20</xref>], <italic>TPP1</italic> [<xref ref-type="bibr" rid="R21">21</xref>], <italic>PPT1</italic> [<xref ref-type="bibr" rid="R22">22</xref>], <italic>ARSG</italic> [<xref ref-type="bibr" rid="R23">23</xref>], <italic>CLN6</italic> [<xref ref-type="bibr" rid="R24">24</xref>], and <italic>ATP13A2</italic> [<xref ref-type="bibr" rid="R25">25</xref>], and one gene, <italic>LGI2</italic>, is associated with genetic epilepsy [<xref ref-type="bibr" rid="R26">26</xref>]. In 2015, using GWAS, Hayward <italic>et al.</italic> [<xref ref-type="bibr" rid="R27">27</xref>] collected the largest set of canine GWAS results. Among these results, the authors found additional candidate genes related to epilepsy in Irish Wolfhounds using 34 cases and 168 controls. However, very little is currently known about the genetic factors that are involved here. Several research efforts are currently focused on the discovery of key genes associated with epilepsy, although the results remain far from unveiling the entire mechanism. This concern leads to our current research.</p>
<p>Among published idiopathic epilepsy studies that have investigated inheritance patterns, various breeds show evidence of autosomal recessive inheritance. Many of these studies also demonstrated polygenic inheritance, indicating that the genetic basis of idiopathic epilepsy is complex in dogs [<xref ref-type="bibr" rid="R4">4</xref>]. In this paper, we used a hybrid method combining GWAS and HotNet2 with Hayward <italic>et al.</italic>’s data [<xref ref-type="bibr" rid="R27">27</xref>] and found 26 significant subnetworks correlated with canine epilepsy. Combined with gene ontology (GO) enrichment analysis, our method not only identified <italic>PPFIA1</italic>, <italic>ASB5</italic>, <italic>SLC1A2</italic> and <italic>MCU</italic> to correspond to significant <italic>P</italic>-values in the GWAS results but also identified the pathogenic genes <italic>PTPRM</italic>, <italic>PTPRD</italic> and <italic>SGCE</italic>, which were omitted by the GWAS analysis. Among the above seven genes, <italic>PPFIA1</italic> [<xref ref-type="bibr" rid="R28">28</xref>], <italic>SLC1A2</italic> [<xref ref-type="bibr" rid="R29">29</xref>], <italic>PTPRM</italic> [<xref ref-type="bibr" rid="R30">30</xref>] and <italic>SGCE</italic> [<xref ref-type="bibr" rid="R31">31</xref>] were reported to be associated with epilepsy, and the others were associated with mental illness [<xref ref-type="bibr" rid="R32">32</xref>–<xref ref-type="bibr" rid="R34">34</xref>]. Moreover, drug enrichment analysis showed that the subnetworks we identified are capable of enriching anti-epilepsy drugs. In view of the combination therapy in cancer enhances efficacy and reduces drug resistance compared to the mono-therapy approach [<xref ref-type="bibr" rid="R35">35</xref>], we believe that this strategy can work on epilepsy. When targets of different anti-epilepsy drugs are enriched in the same subnetwork, their combinations are also more likely to effectively treat epilepsy. Ultimately, 22 drug combinations were obtained, one of which was confirmed in the Drug Combination database (DCDB, <ext-link ext-link-type="uri" xlink:href="https://omictools.com/drug-combination-database-tool">https://omictools.com/drug-combination-database-tool</ext-link>). The results of this study showed the effectiveness of our method in exploring the pathogenesis of canine epilepsy, and this approach increases cost efficiency for anti-epilepsy drug discovery.</p>
</sec>
<sec id="s2">
<title>RESULTS AND DISCUSSION</title>
<sec id="s2_1">
<title>Replication of the GWAS experiment</title>
<p>MLogit [<xref ref-type="bibr" rid="R36">36</xref>] was used to analyze the GWAS data. Our experiment completely replicated the results of the previous GWAS and achieved high consistency.</p>
<p>By using the NCBI SNP database (<ext-link ext-link-type="ftp" xlink:href="ftp://ftp.ncbi.nih.gov/snp/organisms/dog_9615/chr_rpts/">ftp://ftp.ncbi.nih.gov/snp/organisms/dog_9615/chr_rpts/</ext-link>), 44,542 SNPs were mapped to dog genes. Among them, the top 82 SNPs passed the Bonferroni thresholded <italic>P</italic>-value of 1.12e-6, and the top 45 SNPs passed the significance test with the empirical thresholded <italic>P</italic>-value of 5e-8. These results are shown in Figure <xref ref-type="fig" rid="F1">1</xref> and Table <xref ref-type="table" rid="T1">1</xref>, and the full dataset is shown in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref>.</p>
<fig id="F1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<title>Manhattan plot of the replicated GWAS experiment</title>
</caption>
<graphic xlink:href="oncotarget-09-13181-g001"></graphic>
</fig>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<title>Results that reached genome-wide significance in Hayward et al.’s study [<xref ref-type="bibr" rid="R27">27</xref>] and our replicated GWAS experiment</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="middle">Disease</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Case/Control</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Name of breeds</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Hayward et al. [<xref ref-type="bibr" rid="R27">27</xref>]<break></break>Top markers<break></break>(chr:position)</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Our replication<break></break>Top markers<break></break>(chr:position)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Idiopathic epilepsy</td>
<td align="center" colspan="1" rowspan="1" valign="middle">34/168</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Irish Wolfhound</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4:7.5–21</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4:7.53–20.824</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2_2">
<title>Identification of significant subnetworks by HotNet2 and subsequent gene ontology analysis</title>
<p>Using automated procedures, HotNet2 identified 26 significant subnetworks (<italic>P</italic> = 0.02, <xref ref-type="supplementary-material" rid="SD2">Supplementary Table 2</xref>), which contained a total of 370 genes. A GO enrichment analysis of the genes was performed for each subnetwork (<ext-link ext-link-type="uri" xlink:href="http://www.geneontology.org">http://www.geneontology.org</ext-link>). Intriguingly, the results of the GO analysis from 4 of the 26 subnetworks were associated with epilepsy, as shown in Table <xref ref-type="table" rid="T2">2</xref>.</p>
<table-wrap id="T2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<title>Results of the subnetwork GO analyses</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="middle">Subnetwork index</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Gene ontology analysis</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Genes</th>
<th align="center" colspan="1" rowspan="1" valign="middle"><italic>P</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="2" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GO molecular function complete</td>
<td align="left" colspan="1" rowspan="1" valign="middle"></td>
<td align="left" colspan="1" rowspan="1" valign="middle"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">protein tyrosine phosphatase activity</td>
<td align="center" colspan="1" rowspan="1" valign="middle">PTPRD, PTPRK, PTPRM, PTPRT, EYA3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.0126</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GO biological process complete</td>
<td align="left" colspan="1" rowspan="1" valign="middle"></td>
<td align="left" colspan="1" rowspan="1" valign="middle"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">amino acid transmembrane transport</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SLC36A3, SLC1A2, SLC38A2, SLC7A8, SLC38A10, SLC38A11</td>
<td align="center" colspan="1" rowspan="1" valign="middle">6.06E-06</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="middle">11</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GO molecular function complete</td>
<td align="left" colspan="1" rowspan="1" valign="middle"></td>
<td align="left" colspan="1" rowspan="1" valign="middle"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">cAMP response element binding</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CREB3L1, CREB3L2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.0316</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3" valign="middle">17</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GO cellular component complete</td>
<td align="left" colspan="1" rowspan="1" valign="middle"></td>
<td align="left" colspan="1" rowspan="1" valign="middle"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">sarcoglycan complex</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SGCD, SGCZ, SGCE</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.77E-06</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">uniplex complex</td>
<td align="center" colspan="1" rowspan="1" valign="middle">MCU, MICU1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.00202</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The first subnetwork was the largest, containing 50 genes. The enrichment term used was “protein tyrosine phosphatase activity,” which is a significant molecular function, as previous studies have shown that mutations in protein tyrosine phosphatase can cause progressive myoclonus epilepsy [<xref ref-type="bibr" rid="R37">37</xref>–<xref ref-type="bibr" rid="R39">39</xref>]. Specifically, the genes involved in protein tyrosine phosphatase activity in this subnetwork are <italic>PTPRD</italic>, <italic>PTPRK</italic>, <italic>PTPRM</italic>, <italic>PTPRT</italic> and <italic>EYA3</italic>. Among these five genes, <italic>PTPRM</italic> is associated with mesial temporal lobe epilepsy [<xref ref-type="bibr" rid="R30">30</xref>], and <italic>PTPRD</italic> is implicated in the neurological disorder restless legs syndrome (RLS) [<xref ref-type="bibr" rid="R32">32</xref>].</p>
<p><italic>PTPRM</italic> was reported to be involved in mesial temporal lobe epilepsy [<xref ref-type="bibr" rid="R30">30</xref>]. <italic>PTPRM</italic> encodes a cell surface receptor that is a homophilic cell-cell adhesion molecule expressed in neuronal, glial and endothelial cells [<xref ref-type="bibr" rid="R40">40</xref>]. <italic>PTPRM</italic> is part of the network associated with cell growth and differentiation mechanisms [<xref ref-type="bibr" rid="R41">41</xref>] and is also associated with neurite outgrowth [<xref ref-type="bibr" rid="R42">42</xref>]. Santos <italic>et al</italic> quantified <italic>PTPRM</italic> transcripts in hippocampal samples from patients and controls and observed up-regulated <italic>PTPRM</italic> transcript levels in the patient group compared with the control group [<xref ref-type="bibr" rid="R30">30</xref>]. Their results indicated involvement of <italic>PTPRM</italic> in the predisposition to mesial temporal lobe epilepsy.</p>
<p>Some evidence has shown that variants in the 5′ UTR of <italic>PTPRD</italic> are implicated in the neurological disorder RLS. These RLS-associated SNPs consist of ten noncoding exons contained in two known long splice variants expressed predominantly in fetal and adult brain tissue [<xref ref-type="bibr" rid="R32">32</xref>]. <italic>PTPRD</italic> encodes protein tyrosine phosphatase receptor type D, and it is associated with the regulation of synapse development and function [<xref ref-type="bibr" rid="R43">43</xref>]. RLS is the same neurological disease as epilepsy, and therefore, <italic>PTPRD</italic> may play a role in epilepsy.</p>
<p>Although the <italic>P</italic>-values of <italic>PTPRM</italic> and <italic>PTPRD</italic> were 0.0816 and 0.0723, respectively, which were not significant in the GWAS, they were highlighted by HotNet2. The other three protein tyrosine phosphatases were not associated with any relevant reports but may be involved in epilepsy etiology and deserve further study. Along with the other four genes, <italic>PTPRD</italic> was associated with two other latent vital genes discovered by HotNet2, <italic>PPFIA1</italic> and <italic>ASB5</italic>, which are marked as two dashed circles in Figure <xref ref-type="fig" rid="F2">2</xref>. <italic>PPFIA1</italic> encodes the Liprin-a1 protein, which contains 1202 amino acid residues with a molecular weight of approximately 136 kDa. Yin <italic>et al</italic> first reported that Liprin-a1 protein exists in the temporal neocortex of intractable epilepsy patients. They found that the expression level of Liprin-a1 was significantly higher in intractable temporal lobe epilepsy patients than in controls. Their results suggested that increased expression of Liprin-a1 in the brain is associated with human intractable epilepsy [<xref ref-type="bibr" rid="R28">28</xref>]. In addition, <italic>ASB5</italic> encodes a protein in the ankyrin repeat and SOCS box-containing (ASB) family of proteins. Novel copy number variations (CNVs) in <italic>ASB5</italic> have been identified in children with autism [<xref ref-type="bibr" rid="R33">33</xref>]. Davis <italic>et al</italic> found a 166-kb deletion on chromosome 4q34.2 in two of three trizygotic triplets, and this deletion included <italic>ASB5</italic>. Another study reported that deletions in this chromosome region are associated with several features including mild mental retardation, velo-cardio-facial (VCF) syndrome-like features, and finger clinodactyly [<xref ref-type="bibr" rid="R33">33</xref>]. Considering that autism and epilepsy are both neurological diseases, these results demonstrate the effectiveness of this method.</p>
<fig id="F2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<title>The topologies of genes involved in protein tyrosine phosphatase activity</title>
</caption>
<graphic xlink:href="oncotarget-09-13181-g002"></graphic>
</fig>
<p>The fourth subnetwork contained 31 genes. The GO biological process results are shown in Table <xref ref-type="table" rid="T2">2</xref>. The amino acid transmembrane transport function gene results yielded <italic>SLC36A3</italic>, <italic>SLC1A2</italic>, <italic>SLC38A2</italic>, <italic>SLC7A8</italic>, <italic>SLC38A10</italic>, and <italic>SLC38A11</italic>. All these genes transcribe proteins in the solute carrier family. Mutations in <italic>SLC1A2</italic> are critical causes of epileptic encephalopathies [<xref ref-type="bibr" rid="R29">29</xref>]. <italic>SLC1A2</italic> encodes one of the major glutamate transporters; mutations in <italic>SLC1A2</italic> in mice cause impaired glutamate uptake, and the resulting excess glutamate leads to subsequent excitotoxicity. The previous study defined a type of SLC1A2 encephalopathy and highlighted the importance of <italic>SLC1A2</italic> as a glutamatergic gene associated with epileptic encephalopathies [<xref ref-type="bibr" rid="R29">29</xref>]. The other genes, <italic>SLC36A3</italic>, <italic>SLC38A2</italic>, and <italic>SLC7A8</italic>, are associated with the transport of anti-epilepsy drugs [<xref ref-type="bibr" rid="R44">44</xref>–<xref ref-type="bibr" rid="R46">46</xref>].</p>
<p>HotNet2 also identified a subnetwork containing eleven proteins. The GO molecular functions are presented in Table <xref ref-type="table" rid="T2">2</xref>. Studies have shown that inhibition of cAMP response element binding protein (CREB) transcription can shorten the duration of status epilepticus [<xref ref-type="bibr" rid="R47">47</xref>]. In this subnetwork, CREB3L1 and CREB3L2 were classified as belonging to the CREB protein family, and therefore, their mutations may regulate CRE transcription and appear to play a role in epilepsy.</p>
<p>The seventeenth subnetwork included eight genes, and the GO cellular components are listed in Table <xref ref-type="table" rid="T2">2</xref>. The three genes involved in the sarcoglycan complex were <italic>SGCD</italic>, <italic>SGCZ</italic>, and <italic>SGCE</italic>. Interestingly, though SGCE was not significantly associated with epilepsy based on the GWAS method alone (<italic>P</italic> = 0.0517), it was highlighted in our method. In fact, it has been reported that epsilon-sarcoglycan (SGCE) mutations can lead to seizures in myoclonus-dystonia patients [<xref ref-type="bibr" rid="R31">31</xref>]. This gene encodes the epsilon member of the sarcoglycan family. Sarcoglycans are transmembrane proteins that are components of the dystrophin-glycoprotein complex, which link the actin cytoskeleton to the extracellular matrix. Studies have indicated that loss-of-function mutations in the SGCE gene are found in approximately 50% (range 20–80%) of epsilon-sarcoglycan cases [<xref ref-type="bibr" rid="R34">34</xref>, <xref ref-type="bibr" rid="R48">48</xref>]. The mitochondrial calcium uniporter (MCU), which is associated with the uniplex complex, is also involved in many neurological diseases [<xref ref-type="bibr" rid="R49">49</xref>]. There is evidence demonstrating that mitochondrial dysfunction contributes to the pathophysiology of epilepsy [<xref ref-type="bibr" rid="R50">50</xref>, <xref ref-type="bibr" rid="R51">51</xref>]. The MCU localizes to the inner membrane and is widely accepted to be responsible for calcium uptake by mitochondria [<xref ref-type="bibr" rid="R52">52</xref>]. Wang <italic>et al</italic> investigated the role of MCU in the rat pilocarpine model of epilepsy, which replicates the key features of temporal lobe epilepsy, and they found that MCU inhibition exerted a neuroprotective effect on seizure-induced brain injury through the mitochondria/ROS/CytC pathway [<xref ref-type="bibr" rid="R49">49</xref>].</p>
<p>In summary, the systems genetics analysis performed here broadened our understanding of mutations in epilepsy. Some gene mutations in these subnetworks have been reported to be significant in epilepsy. These results illustrate the effectiveness of the systems genetics method in determining the pathogenesis of epilepsy.</p>
</sec>
<sec id="s2_3">
<title>Drug enrichment analysis of HotNet2 subnetworks</title>
<p>To test the effectiveness of the HotNet2 method in drug discovery, we counted the enrichment of the drugs in these subnetworks. We collected and sorted 5,452 active drugs corresponding to 2,440 targets in three databases: DrugBank (<ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca">https://www.drugbank.ca</ext-link>), Therapeutic Target Database, (TTD, <ext-link ext-link-type="uri" xlink:href="http://bidd.nus.edu.sg/group/cjttd/">http://bidd.nus.edu.sg/group/cjttd/</ext-link>), and ClinicalTrials (<ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</ext-link>). Among them, there were 79 drugs for the treatment of epilepsy, generating 226 targets. The HotNet2 results based on the relationships of drugs and their targets included 370 genes. We were able to identify 221 active drugs, of which 22 are used for the treatment of epilepsy (Table <xref ref-type="table" rid="T3">3</xref>). The results of a hypergeometric test were significant (<italic>P</italic> = 2.130943e-13), indicating that the HotNet2 approach can markedly enrich anti-epilepsy drugs.</p>
<table-wrap id="T3" orientation="portrait" position="float">
<label>Table 3</label>
<caption>
<title>Drug enrichment of subnetworks</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="middle">Subnetwork index</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Drugs</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Targets</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="13" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Adinazolam</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GABRP</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Clobazam</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GABRP</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Clonazepam</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GABRP</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Diazepam</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GABRP</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Lorazepam</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GABRP</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Meprobamate</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GABRP</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Metharbital</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GABRP</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Nitrazepam</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GABRP</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Primidone</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GABRP</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Propofol</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GABRP</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Topiramate</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GABRP</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Lacosamide</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SCN10A</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Valproic Acid</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SCN10A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="4" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Felbamate</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GRIN3A</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Gabapentin</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GRIN3A</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Ketamine</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GRIN3A</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Phenobarbital</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GRIN3A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="5" valign="middle">14</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CPP-15</td>
<td align="center" colspan="1" rowspan="1" valign="middle">ABAT</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">DP-VPA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">ABAT</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Tiagabine</td>
<td align="center" colspan="1" rowspan="1" valign="middle">ABAT</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Valproic acid</td>
<td align="center" colspan="1" rowspan="1" valign="middle">ABAT</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">Vigabatrin</td>
<td align="center" colspan="1" rowspan="1" valign="middle">ABAT</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">19</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Zonisamide</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CA13</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>We also examined the drug enrichment of a single genetic locus in the GWAS results. We selected the most significant <italic>P</italic>-value of the first 370 genes and obtained 248 active agents, including 15 epilepsy agents. A <italic>P</italic>-value of 1.912487e-06 was obtained using the hypergeometric test. By comparison, the capacity of the HotNet2 method to enrich anti-epilepsy drugs was dramatically higher than that of the GWAS method.</p>
</sec>
<sec id="s2_4">
<title>Potential combinatorial anti-epilepsy drugs</title>
<p>If drugs that treat epilepsy are enriched in the same subnetwork and correspond to different targets, these drugs may be more effective in combination. Through drug enrichment, the second subnetwork contained 13 drugs, of which 11 drugs corresponded to the target GABRP, and the other two drugs corresponded to the target SCN10A. Therefore, we considered 22 potential combinations of anti-epilepsy drugs (Table <xref ref-type="table" rid="T4">4</xref>). In PubMed, we counted the number of co-occurrences of these combinations of drugs and the keyword “epilepsy” in abstracts. As shown in Table <xref ref-type="table" rid="T4">4</xref>, six of the drug combinations were found in a total of more than 100 abstracts. In addition, in the Drug Combination database (DCDB, <ext-link ext-link-type="uri" xlink:href="https://omictools.com/drug-combination-database-tool">https://omictools.com/drug-combination-database-tool</ext-link>), we found that the combination of topiramate and valproic acid (Drug Combination ID: DC000445) has been reported to play a role in anti-epileptic treatment, indicating that this method for identifying drug combinations is reliable.</p>
<table-wrap id="T4" orientation="portrait" position="float">
<label>Table 4</label>
<caption>
<title>Potential drug combinations for epilepsy</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="middle">Index</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Potential combinations of drugs</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Count</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Adinazolam + Lacosamide</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Clobazam + Lacosamide</td>
<td align="center" colspan="1" rowspan="1" valign="middle">17</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Clonazepam +Lacosamide</td>
<td align="center" colspan="1" rowspan="1" valign="middle">10</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Diazepam + Lacosamide</td>
<td align="center" colspan="1" rowspan="1" valign="middle">13</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">5</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Lorazepam + Lacosamide</td>
<td align="center" colspan="1" rowspan="1" valign="middle">12</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">6</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Meprobamate + Lacosamide</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">7</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Metharbital + Lacosamide</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">8</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Nitrazepam + Lacosamide</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">9</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Primidone + Lacosamide</td>
<td align="center" colspan="1" rowspan="1" valign="middle">7</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">10</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Propofol + Lacosamide</td>
<td align="center" colspan="1" rowspan="1" valign="middle">9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">11</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Topiramate + Lacosamide</td>
<td align="center" colspan="1" rowspan="1" valign="middle">58</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">12</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Adinazolam + Valproic Acid</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">13</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Clobazam + Valproic Acid</td>
<td align="center" colspan="1" rowspan="1" valign="middle">142</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">14</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Clonazepam + Valproic Acid</td>
<td align="center" colspan="1" rowspan="1" valign="middle">457</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">15</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Diazepam + Valproic Acid</td>
<td align="center" colspan="1" rowspan="1" valign="middle">407</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">16</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Lorazepam + Valproic Acid</td>
<td align="center" colspan="1" rowspan="1" valign="middle">115</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">17</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Meprobamate + Valproic Acid</td>
<td align="center" colspan="1" rowspan="1" valign="middle">9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">18</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Metharbital + Valproic Acid</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">19</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Nitrazepam + Valproic Acid</td>
<td align="center" colspan="1" rowspan="1" valign="middle">35</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">20</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Primidone + Valproic Acid</td>
<td align="center" colspan="1" rowspan="1" valign="middle">272</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">21</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Propofol + Valproic Acid</td>
<td align="center" colspan="1" rowspan="1" valign="middle">41</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">22</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Topiramate + Valproic Acid</td>
<td align="center" colspan="1" rowspan="1" valign="middle">521</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec id="s3">
<title>MATERIALS AND METHODS</title>
<sec id="s3_1">
<title>Data &amp; materials</title>
<p>The data were from a study by Hayward <italic>et al.</italic> [<xref ref-type="bibr" rid="R27">27</xref>], an extensive dog genotyping dataset with 4,224 samples genotyped on a semicustom 180,000 SNP array for several complex traits. Among the most common recorded diseases collected in these data, there were 7 across-breed phenotypes (canine hip dysplasia, elbow dysplasia, cranial cruciate ligament disease, mast cell tumor, lymphoma, portosystemic vascular anomalies and mitral valve degeneration) and 5 within-breed phenotypes (idiopathic epilepsy in Irish Wolfhounds, granulomatous colitis in Boxers and Bulldogs, lymphoma in Golden Retrievers, mast cell tumor in Labrador Retrievers and portosystemic vascular anomalies in Yorkshire Terriers). To avoid the diversity between across-breed individuals, we retained the disease idiopathic epilepsy (IE) in Irish Wolfhounds, which consisted of 200 individuals (34 cases and 168 controls) and 160,727 SNPs. Case dogs were diagnosed by metabolic screening, magnetic resonance imaging and EEG, while control dogs were older than 5 years and without a history of seizures.</p>
<p>The raw GWAS data were preprocessed by PLINK v1.9 (<ext-link ext-link-type="uri" xlink:href="http://zzz.bwh.harvard.edu/plink/tutorial.shtml">http://zzz.bwh.harvard.edu/plink/tutorial.shtml</ext-link>). Only SNPs with a minor allele frequency (MAF) &gt; 0.05 and Hardy–Weinberg test (HWE) &lt; 0.001 in these individuals were included. After quality control, 89,085 SNPs remained.</p>
</sec>
<sec id="s3_2">
<title>Replication of the GWAS experiment using multiple logistic regression</title>
<p>Logistic regression (LR) is a suitable algorithm for associating phenotypes with different genotypes. Assuming <italic>Y</italic> is the binary genotype variable, and <italic>x</italic> is the phenotype variable (continuous or discrete), we can obtain the association of <italic>y</italic> and <italic>x</italic> by LR. The goal of LR is to model <inline-formula><mml:math id="eq-001"><mml:mrow><mml:mi>p</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>x</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>≡</mml:mo><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mi>Y</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>|</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>. In LR, the probability <inline-formula><mml:math id="eq-002"><mml:mrow><mml:mi>p</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>x</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is modeled by <inline-formula><mml:math id="eq-003"><mml:mrow><mml:mi>p</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>x</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula>, which can be conveniently converted to <inline-formula><mml:math id="eq-004"><mml:mrow><mml:mi>log</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi>p</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>x</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>x</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:math></inline-formula>. To test <inline-formula><mml:math id="eq-005"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>:</mml:mo><mml:mi>β</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula> vs. <inline-formula><mml:math id="eq-006"><mml:mrow><mml:msub><mml:mi mathvariant="italic">H</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>:</mml:mo><mml:mi mathvariant="italic">β</mml:mi><mml:mo>≠</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>, the test statistic <inline-formula><mml:math id="eq-007"><mml:mrow><mml:mi>Z</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msqrt><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mi>a</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula> is used.</p>
<p>To match the multinomial nature of the genotype data, we use multinomial logistic regression (MLogit, or multiclass logistic regression [<xref ref-type="bibr" rid="R36">36</xref>]) to calculate the association of <italic>y</italic> and <italic>x</italic>. We denote the genotype variable <italic>y</italic> = 0, 1, and 2, and the MLogit model is as follows:<disp-formula id="uneq001"><mml:math id="eq-008"><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>|</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula><disp-formula id="uneq002"><mml:math id="eq-009"><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>y</mml:mi><mml:mo>≤</mml:mo><mml:mn>1</mml:mn><mml:mo>|</mml:mo><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo>→</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula><disp-formula id="uneq003"><mml:math id="eq-010"><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>y</mml:mi><mml:mo>≤</mml:mo><mml:mn>2</mml:mn><mml:mo>|</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="uneq004"><mml:math id="eq-011"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>|</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="uneq005"><mml:math id="eq-012"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>|</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math></disp-formula><disp-formula id="uneq006"><mml:math id="eq-013"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo>|</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></disp-formula></p>
<p>We can estimate the parameters <inline-formula><mml:math id="eq-014"><mml:mrow><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> using the maximum likelihood method and obtain the probabilities <italic>p</italic><sub><italic>1</italic></sub>, <italic>p</italic><sub><italic>2</italic></sub> and <italic>p</italic><sub><italic>3</italic></sub>. In this study, we used the R package “MLogit” [<xref ref-type="bibr" rid="R36">36</xref>] to obtain the estimators.</p>
</sec>
<sec id="s3_3">
<title>Using the HotNet2 algorithm to find subnetworks related to epilepsy</title>
<p>HotNet2 (HotNet diffusion-oriented subnetworks) performs well for finding significant subnetworks, which consist of genes with a higher mutation tendency than expected by chance in a large gene interaction network. HotNet2 is based on a heat diffusion kernel algorithm by considering random walks with restarts [<xref ref-type="bibr" rid="R53">53</xref>].</p>
<p>The main inputs to HotNet2 include a heat vector, which contains the score of each gene and the interactions among the corresponding gene pairs. First, to compute the heat vector for each gene, the sorted <italic>P</italic>-values of SNPs in the GWAS were used after removing redundancy. Specifically, the minimum GWAS <italic>P</italic>-value of the SNPs in the gene was set as the final heat value of the gene. Thus, 12,355 genes with their corresponding <italic>P</italic>-values were obtained. To avoid information loss of the amount of gene mutations, Spearman testing was performed to indicate the positive correlations between the number of gene mutations and the negative logarithm of the minimum <italic>P</italic>-value (i.e., credibility). Here, the correlation value for Spearman testing was 0.294, and the credibility was 9.0459e-245, i.e., the minimum <italic>P</italic>-value contains information on the number of mutations. Afterwards, the top 20% of genes (<italic>n</italic> = 2471) were selected as the input, and the negative log base 10 of each <italic>P</italic>-value was used for the computation formula. Second, to obtain the interactions used for HotNet2, <italic>canis lupus familiaris</italic> protein-protein interaction networks were derived from the STRING database (STRING, <ext-link ext-link-type="uri" xlink:href="http://www.string-db.org">http://www.string-db.org</ext-link>). As the default score threshold is usually 400 [<xref ref-type="bibr" rid="R54">54</xref>], interactions with scores lower than 400 were discarded.</p>
<p>The parameter in HotNet2 was set as the default, β = 0.4, as cited by Leiserson <italic>et al</italic> [<xref ref-type="bibr" rid="R53">53</xref>]. Finally, the most significant (<italic>P</italic> &lt; 0.05) subnetworks were identified.</p>
</sec>
<sec id="s3_4">
<title>Study flowchart</title>
<p>A flowchart of this study is shown in Figure <xref ref-type="fig" rid="F3">3</xref>.</p>
<fig id="F3" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<title>Study flowchart</title>
<p>(<bold>A</bold>) The associations of genes with canine epilepsy were calculated by the GWAS method. Some genes were significantly associated with canine epilepsy (<italic>P</italic> &lt; 0.05, marked with orange), and some were not (marked by blue in the figure). (<bold>B</bold>) The significant subnetworks related to canine epilepsy were found using the HotNet2 method. (<bold>C</bold>) GO enrichment analysis of each subnetwork led to enhancement of the GWAS results and allowed exploration of the pathogenesis of canine epilepsy. (<bold>D</bold>) Relationship statistics of single drug-gene pairs that passed the enrichment testing of the anti-epilepsy drugs in these subnetworks. (<bold>E</bold>) These drug combinations are likely to produce synergistic effects if separate target genes of different drugs co-occur in a vital HotNet2 subnetwork.</p>
</caption>
<graphic xlink:href="oncotarget-09-13181-g003"></graphic>
</fig>
</sec>
</sec>
<sec id="s4">
<title>CONCLUSIONS</title>
<p>The domestic dog (<italic>Canis familiaris</italic>) is not only a faithful partner of humans but also an excellent model animal for studying human diseases, as the dog genome and clinical manifestations are extremely similar to those of humans [<xref ref-type="bibr" rid="R7">7</xref>]. In this study, the genotype and epilepsy phenotype data of Hayward <italic>et al.</italic> [<xref ref-type="bibr" rid="R27">27</xref>] were used to explore the pathogenesis of canine epilepsy in a combined method using GWAS and HotNet2.</p>
<p>Using the combination of GWAS and HotNet2, we ultimately identified 26 subnetworks associated with canine epilepsy. Through GO enrichment analysis and a literature review, we focused on the relationship between gene mutations and epilepsy mechanisms in four subnetworks. We automatically identified <italic>PTPRD</italic>, <italic>PPFIA1</italic>, <italic>ASB5</italic>, <italic>SLC1A2</italic>, and <italic>SGCE</italic> from a large-scale interaction network. <italic>PTPRM</italic>, <italic>PTPRD</italic> and <italic>SGCE</italic> were of particular interest, as they were not significant results of the GWAS and, thus, demonstrated the power of this method. Moreover, <italic>PTPRM</italic>, <italic>PPFIA1</italic>, <italic>SLC1A2</italic>, and <italic>SGCE</italic> were confirmed to be associated with epilepsy, while <italic>PTPRD</italic>, <italic>ASB5</italic>, and <italic>MCU</italic> were involved in neurological disorders. This evidence suggests that the method for key gene discovery is reliable.</p>
<p>In addition, we performed drug enrichment on each subnetwork, resulting in 221 active drugs, of which 22 were drugs used for the treatment of epilepsy. The hypergeometric test was extremely significant and was stronger than the single-site GWAS method of drug enrichment. If targets of agents correspond to different target genes in the same subnetwork, their combinations are likely to induce synergistic effects. We found 22 potential combinations of anti-epilepsy drug treatments. One of these drug combinations, topiramate and valproic acid (DrugCombination_ID: DC000445), have been confirmed by the DCDB database for the treatment of epilepsy.</p>
<p>In summary, this study demonstrated that the combined GWAS and HotNet2 methods can effectively exploit the pathogenic factors of epilepsy and be used to identify potential drug combinations. Moreover, not only is the present approach helpful for epilepsy, but it will also be useful for exploring the pathogenic mechanisms of other diseases and potential drug combinations.</p>
</sec>
<sec id="s5" sec-type="supplementary-material">
<title>SUPPLEMENTARY MATERIALS TABLES</title>
<supplementary-material content-type="local-data" id="SD1">
<media id="d35e1975" mime-subtype="pdf" mimetype="application" orientation="portrait" position="anchor" xlink:href="oncotarget-09-13181-s001.pdf"></media>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD2">
<media id="d35e1977" mime-subtype="xlsx" mimetype="application" orientation="portrait" position="anchor" xlink:href="oncotarget-09-13181-s002.xlsx"></media>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD3">
<media id="d35e1979" mime-subtype="xlsx" mimetype="application" orientation="portrait" position="anchor" xlink:href="oncotarget-09-13181-s003.xlsx"></media>
</supplementary-material>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="con">
<p>
<bold>Author contributions</bold>
</p>
<p>Ze-Jia Cui and Ye-Mao Liu generated the data, Ze-Jia Cui analyzed the data, Qiang Zhu discussed the algorithm, Jingbo Xia and Ze-Jia Cui drafted the manuscript, Hong-Yu Zhang designed the entire pipeline. All authors approved the final manuscript.</p>
</fn>
</fn-group>
<ack>
<title>ACKNOWLEDGMENTS AND FUNDING</title>
<p>This work was supported by the National Natural Science Foundation of China (Grant No. 61202305).</p>
</ack>
<fn-group>
<fn fn-type="COI-statement">
<p>
<bold>CONFLICTS OF INTEREST</bold>
</p>
<p>The authors declare no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>REFERENCES</title>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Xia</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Lin</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Ou</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Pan</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Comparative study of joint bioinformatics analysis of underlying potential of ‘neurimmiR’, miR-212-3P/miR-132-3P, being involved in epilepsy and its emerging role in human cancer</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>40668</fpage>
<lpage>40682</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.16541">https://doi.org/10.18632/oncotarget.16541</ext-link>
</comment>
<pub-id pub-id-type="pmid">28380454</pub-id>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Iori</surname>
<given-names>V</given-names>
</name>
<name name-style="western">
<surname>Aronica</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Vezzani</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Epigenetic control of epileptogenesis by miR-146a</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>45040</fpage>
<lpage>45041</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.18364">https://doi.org/10.18632/oncotarget.18364</ext-link>
</comment>
<pub-id pub-id-type="pmid">28589912</pub-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Löscher</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy</article-title>
<source/>Epilepsy Res
          <year>2002</year>
<volume>50</volume>
<fpage>105</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">12151122</pub-id>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ekenstedt</surname>
<given-names>KJ</given-names>
</name>
<name name-style="western">
<surname>Oberbauer</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Inherited Epilepsy in Dogs</article-title>
<source/>Top Companion Anim Med
          <year>2013</year>
<volume>28</volume>
<fpage>51</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">24070682</pub-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Patterson</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>Companion animal medicine in the age of medical genetics</article-title>
<source/>J Vet Intern Med. Med
          <year>2000</year>
<volume>14</volume>
<fpage>1</fpage>
<lpage>9</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Sargan</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>IDID: inherited diseases in dogs: web-based information for canine inherited disease genetics</article-title>
<source/>Mamm Genome
          <year>2004</year>
<volume>15</volume>
<fpage>503</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">15181542</pub-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lindblad-Toh</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Wade</surname>
<given-names>CM</given-names>
</name>
<name name-style="western">
<surname>Mikkelsen</surname>
<given-names>TS</given-names>
</name>
<name name-style="western">
<surname>Karlsson</surname>
<given-names>EK</given-names>
</name>
<name name-style="western">
<surname>Jaffe</surname>
<given-names>DB</given-names>
</name>
<name name-style="western">
<surname>Kamal</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Clamp</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Chang</surname>
<given-names>JL</given-names>
</name>
<name name-style="western">
<surname>Kulbokas</surname>
<given-names>EJ</given-names>
<suffix>3rd</suffix>
</name>
<name name-style="western">
<surname>Zody</surname>
<given-names>MC</given-names>
</name>
<name name-style="western">
<surname>Mauceli</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Xie</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Breen</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome sequence, comparative analysis and haplotype structure of the domestic dog</article-title>
<source/>Nature
          <year>2005</year>
<volume>438</volume>
<fpage>803</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="pmid">16341006</pub-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Fisher</surname>
<given-names>RS</given-names>
</name>
<name name-style="western">
<surname>Acevedo</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Arzimanoglou</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Bogacz</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Cross</surname>
<given-names>JH</given-names>
</name>
<name name-style="western">
<surname>Elger</surname>
<given-names>CE</given-names>
</name>
<name name-style="western">
<surname>Engel</surname>
<given-names>J</given-names>
<suffix>Jr</suffix>
</name>
<name name-style="western">
<surname>Forsgren</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>French</surname>
<given-names>JA</given-names>
</name>
<name name-style="western">
<surname>Glynn</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Hesdorffer</surname>
<given-names>DC</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>BI</given-names>
</name>
<name name-style="western">
<surname>Mathern</surname>
<given-names>GW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ILAE official report: a practical clinical definition of epilepsy</article-title>
<source/>Epilepsia
          <year>2014</year>
<volume>55</volume>
<fpage>475</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">24730690</pub-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<collab>World Health Organization (WHO)</collab>
</person-group>
<comment>Epilepsy Fact sheet. 2016; URL: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs999/en/">http://www.who.int/mediacentre/factsheets/fs999/en/</ext-link></comment>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>De Risio</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Bhatti</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Muñana</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Penderis</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Stein</surname>
<given-names>V</given-names>
</name>
<name name-style="western">
<surname>Tipold</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Berendt</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Farqhuar</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Fischer</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Long</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Mandigers</surname>
<given-names>PJ</given-names>
</name>
<name name-style="western">
<surname>Matiasek</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Packer</surname>
<given-names>RM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>International veterinary epilepsy task force consensus proposal: diagnostic approach to epilepsy in dogs</article-title>
<source/>BMC Vet Res
          <year>2015</year>
<volume>11</volume>
<fpage>148</fpage>
<pub-id pub-id-type="pmid">26316175</pub-id>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kearsley-Fleet</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>O’Neill</surname>
<given-names>DG</given-names>
</name>
<name name-style="western">
<surname>Volk</surname>
<given-names>HA</given-names>
</name>
<name name-style="western">
<surname>Church</surname>
<given-names>DB</given-names>
</name>
<name name-style="western">
<surname>Brodbelt</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Prevalence and risk factors for canine epilepsy of unknown origin in the UK</article-title>
<source/>Vet Rec
          <year>2013</year>
<volume>172</volume>
<fpage>338</fpage>
<pub-id pub-id-type="pmid">23300065</pub-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Johannessen Landmark</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Johannessen</surname>
<given-names>SI</given-names>
</name>
</person-group>
<article-title>Pharmacological management of epilepsy: recent advances and future prospects</article-title>
<source/>Drugs
          <year>2008</year>
<volume>68</volume>
<fpage>1925</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">18778117</pub-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Klein</surname>
<given-names>RJ</given-names>
</name>
<name name-style="western">
<surname>Zeiss</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Chew</surname>
<given-names>EY</given-names>
</name>
<name name-style="western">
<surname>Tsai</surname>
<given-names>JY</given-names>
</name>
<name name-style="western">
<surname>Sackler</surname>
<given-names>RS</given-names>
</name>
<name name-style="western">
<surname>Haynes</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Henning</surname>
<given-names>AK</given-names>
</name>
<name name-style="western">
<surname>SanGiovanni</surname>
<given-names>JP</given-names>
</name>
<name name-style="western">
<surname>Mane</surname>
<given-names>SM</given-names>
</name>
<name name-style="western">
<surname>Mayne</surname>
<given-names>ST</given-names>
</name>
<name name-style="western">
<surname>Bracken</surname>
<given-names>MB</given-names>
</name>
<name name-style="western">
<surname>Ferris</surname>
<given-names>FL</given-names>
</name>
<name name-style="western">
<surname>Ott</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Complement factor H polymorphism in age-related macular degeneration</article-title>
<source/>Science
          <year>2005</year>
<volume>308</volume>
<fpage>385</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">15761122</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kasperaviciūte</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Catarino</surname>
<given-names>CB</given-names>
</name>
<name name-style="western">
<surname>Heinzen</surname>
<given-names>EL</given-names>
</name>
<name name-style="western">
<surname>Depondt</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Cavalleri</surname>
<given-names>GL</given-names>
</name>
<name name-style="western">
<surname>Caboclo</surname>
<given-names>LO</given-names>
</name>
<name name-style="western">
<surname>Tate</surname>
<given-names>SK</given-names>
</name>
<name name-style="western">
<surname>Jamnadas-Khoda</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Chinthapalli</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Clayton</surname>
<given-names>LM</given-names>
</name>
<name name-style="western">
<surname>Shianna</surname>
<given-names>KV</given-names>
</name>
<name name-style="western">
<surname>Radtke</surname>
<given-names>RA</given-names>
</name>
<name name-style="western">
<surname>Mikati</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study</article-title>
<source/>Brain
          <year>2010</year>
<volume>133</volume>
<fpage>2136</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="pmid">20522523</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Guo</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Baum</surname>
<given-names>LW</given-names>
</name>
<name name-style="western">
<surname>Sham</surname>
<given-names>PC</given-names>
</name>
<name name-style="western">
<surname>Wong</surname>
<given-names>V</given-names>
</name>
<name name-style="western">
<surname>Ng</surname>
<given-names>PW</given-names>
</name>
<name name-style="western">
<surname>Lui</surname>
<given-names>CH</given-names>
</name>
<name name-style="western">
<surname>Sin</surname>
<given-names>NC</given-names>
</name>
<name name-style="western">
<surname>Tsoi</surname>
<given-names>TH</given-names>
</name>
<name name-style="western">
<surname>Tang</surname>
<given-names>CS</given-names>
</name>
<name name-style="western">
<surname>Kwan</surname>
<given-names>JS</given-names>
</name>
<name name-style="western">
<surname>Yip</surname>
<given-names>BH</given-names>
</name>
<name name-style="western">
<surname>Xiao</surname>
<given-names>SM</given-names>
</name>
<name name-style="western">
<surname>Thomas</surname>
<given-names>GN</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Two-stage genome-wide association study identifies variants in CAMSAP1L1 as susceptibility loci for epilepsy in Chinese</article-title>
<source/>Hum Mol Genet
          <year>2012</year>
<volume>21</volume>
<fpage>1184</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">22116939</pub-id>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Buono</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Genome wide association studies (GWAS) and common forms of human epilepsy</article-title>
<source/>Epilepsy Behav
          <year>2013</year>
<volume>28</volume>
<fpage>S63</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">23756483</pub-id>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lohi</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Young</surname>
<given-names>EJ</given-names>
</name>
<name name-style="western">
<surname>Fitzmaurice</surname>
<given-names>SN</given-names>
</name>
<name name-style="western">
<surname>Rusbridge</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Chan</surname>
<given-names>EM</given-names>
</name>
<name name-style="western">
<surname>Vervoort</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Turnbull</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Zhao</surname>
<given-names>XC</given-names>
</name>
<name name-style="western">
<surname>Ianzano</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Paterson</surname>
<given-names>AD</given-names>
</name>
<name name-style="western">
<surname>Sutter</surname>
<given-names>NB</given-names>
</name>
<name name-style="western">
<surname>Ostrander</surname>
<given-names>EA</given-names>
</name>
<name name-style="western">
<surname>André</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expanded Repeat in Canine Epilepsy</article-title>
<source/>Science
          <year>2005</year>
<volume>307</volume>
<fpage>81</fpage>
<pub-id pub-id-type="pmid">15637270</pub-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Katz</surname>
<given-names>ML</given-names>
</name>
<name name-style="western">
<surname>Khan</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Awano</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Shahid</surname>
<given-names>SA</given-names>
</name>
<name name-style="western">
<surname>Siakotos</surname>
<given-names>AN</given-names>
</name>
<name name-style="western">
<surname>Johnson</surname>
<given-names>GS</given-names>
</name>
</person-group>
<article-title>A mutation in the CLN8 gene in English Setter dogs with neuronal ceroid-lipofuscinosis</article-title>
<source/>Biochem Biophys Res Commun
          <year>2005</year>
<volume>327</volume>
<fpage>541</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">15629147</pub-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Melville</surname>
<given-names>SA</given-names>
</name>
<name name-style="western">
<surname>Wilson</surname>
<given-names>CL</given-names>
</name>
<name name-style="western">
<surname>Chiang</surname>
<given-names>CS</given-names>
</name>
<name name-style="western">
<surname>Studdert</surname>
<given-names>VP</given-names>
</name>
<name name-style="western">
<surname>Lingaas</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Wilton</surname>
<given-names>AN</given-names>
</name>
</person-group>
<article-title>A mutation in canine CLN5 causes neuronal ceroid lipofuscinosis in Border collie dogs</article-title>
<source/>Genomics
          <year>2005</year>
<volume>86</volume>
<fpage>287</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="pmid">16033706</pub-id>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Awano</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Katz</surname>
<given-names>ML</given-names>
</name>
<name name-style="western">
<surname>O’Brien</surname>
<given-names>DP</given-names>
</name>
<name name-style="western">
<surname>Taylor</surname>
<given-names>JF</given-names>
</name>
<name name-style="western">
<surname>Evans</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Khan</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Sohar</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Lobel</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Johnson</surname>
<given-names>GS</given-names>
</name>
</person-group>
<article-title>A mutation in the cathepsin D gene (CTSD) in American Bulldogs with neuronal ceroid lipofuscinosis</article-title>
<source/>Mol Genet Metab
          <year>2006</year>
<volume>87</volume>
<fpage>341</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">16386934</pub-id>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Awano</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Katz</surname>
<given-names>ML</given-names>
</name>
<name name-style="western">
<surname>O’Brien</surname>
<given-names>DP</given-names>
</name>
<name name-style="western">
<surname>Sohar</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Lobel</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Coates</surname>
<given-names>JR</given-names>
</name>
<name name-style="western">
<surname>Khan</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Johnson</surname>
<given-names>GC</given-names>
</name>
<name name-style="western">
<surname>Giger</surname>
<given-names>U</given-names>
</name>
<name name-style="western">
<surname>Johnson</surname>
<given-names>GS</given-names>
</name>
</person-group>
<article-title>A frame shift mutation in canine TPP1 (the ortholog of human CLN2) in a juvenile Dachshund with neuronal ceroid lipofuscinosis</article-title>
<source/>Mol Genet Metab
          <year>2006</year>
<volume>89</volume>
<fpage>254</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">16621647</pub-id>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Sanders</surname>
<given-names>DN</given-names>
</name>
<name name-style="western">
<surname>Farias</surname>
<given-names>FH</given-names>
</name>
<name name-style="western">
<surname>Johnson</surname>
<given-names>GS</given-names>
</name>
<name name-style="western">
<surname>Chiang</surname>
<given-names>V</given-names>
</name>
<name name-style="western">
<surname>Cook</surname>
<given-names>JR</given-names>
</name>
<name name-style="western">
<surname>O’Brien</surname>
<given-names>DP</given-names>
</name>
<name name-style="western">
<surname>Hofmann</surname>
<given-names>SL</given-names>
</name>
<name name-style="western">
<surname>Lu</surname>
<given-names>JY</given-names>
</name>
<name name-style="western">
<surname>Katz</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>A mutation in canine PPT1 causes early onset neuronal ceroid lipofuscinosis in a Dachshund</article-title>
<source/>Mol Genet Metab
          <year>2010</year>
<volume>100</volume>
<fpage>349</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="pmid">20494602</pub-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Abitbol</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Thibaud</surname>
<given-names>JL</given-names>
</name>
<name name-style="western">
<surname>Olby</surname>
<given-names>NJ</given-names>
</name>
<name name-style="western">
<surname>Hitte</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Puech</surname>
<given-names>JP</given-names>
</name>
<name name-style="western">
<surname>Maurer</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Pilot-Storck</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Hédan</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Dréano</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Brahimi</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Delattre</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>André</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Gray</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A canine Arylsulfatase G (ARSG) mutation leading to a sulfatase deficiency is associated with neuronal ceroid lipofuscinosis</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2010</year>
<volume>107</volume>
<fpage>14775</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="pmid">20679209</pub-id>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Katz</surname>
<given-names>ML</given-names>
</name>
<name name-style="western">
<surname>Farias</surname>
<given-names>FH</given-names>
</name>
<name name-style="western">
<surname>Sanders</surname>
<given-names>DN</given-names>
</name>
<name name-style="western">
<surname>Zeng</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Khan</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Johnson</surname>
<given-names>GS</given-names>
</name>
<name name-style="western">
<surname>O’Brien</surname>
<given-names>DP</given-names>
</name>
</person-group>
<article-title>A missense mutation in canine CLN6 in an Australian shepherd with neuronal ceroid lipofuscinosis</article-title>
<source/>J Biomed Biotechnol
          <year>2011</year>
<volume>2011</volume>
<fpage>198042</fpage>
<pub-id pub-id-type="pmid">21234413</pub-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Farias</surname>
<given-names>FH</given-names>
</name>
<name name-style="western">
<surname>Zeng</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Johnson</surname>
<given-names>GS</given-names>
</name>
<name name-style="western">
<surname>Wininger</surname>
<given-names>FA</given-names>
</name>
<name name-style="western">
<surname>Taylor</surname>
<given-names>JF</given-names>
</name>
<name name-style="western">
<surname>Schnabel</surname>
<given-names>RD</given-names>
</name>
<name name-style="western">
<surname>McKay</surname>
<given-names>SD</given-names>
</name>
<name name-style="western">
<surname>Sanders</surname>
<given-names>DN</given-names>
</name>
<name name-style="western">
<surname>Lohi</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Seppälä</surname>
<given-names>EH</given-names>
</name>
<name name-style="western">
<surname>Wade</surname>
<given-names>CM</given-names>
</name>
<name name-style="western">
<surname>Lindblad-Toh</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>O’Brien</surname>
<given-names>DP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A truncating mutation in ATP13A2 is responsible for adult-onset neuronal ceroid lipofuscinosis in Tibetan terriers</article-title>
<source/>Neurobiol Dis
          <year>2011</year>
<volume>42</volume>
<fpage>468</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="pmid">21362476</pub-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Seppälä</surname>
<given-names>EH</given-names>
</name>
<name name-style="western">
<surname>Jokinen</surname>
<given-names>TS</given-names>
</name>
<name name-style="western">
<surname>Fukata</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Fukata</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Webster</surname>
<given-names>MT</given-names>
</name>
<name name-style="western">
<surname>Karlsson</surname>
<given-names>EK</given-names>
</name>
<name name-style="western">
<surname>Kilpinen</surname>
<given-names>SK</given-names>
</name>
<name name-style="western">
<surname>Steffen</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Dietschi</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Leeb</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Eklund</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Zhao</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Rilstone</surname>
<given-names>JJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>LGI2 truncation causes a remitting focal epilepsy in dogs. Plos Genetics</article-title>
<source/>PLoS Genet
          <year>2011</year>
<volume>7</volume>
<fpage>e1002194</fpage>
<pub-id pub-id-type="pmid">21829378</pub-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Hayward</surname>
<given-names>JJ</given-names>
</name>
<name name-style="western">
<surname>Castelhano</surname>
<given-names>MG</given-names>
</name>
<name name-style="western">
<surname>Oliveira</surname>
<given-names>KC</given-names>
</name>
<name name-style="western">
<surname>Corey</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Balkman</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Baxter</surname>
<given-names>TL</given-names>
</name>
<name name-style="western">
<surname>Casal</surname>
<given-names>ML</given-names>
</name>
<name name-style="western">
<surname>Center</surname>
<given-names>SA</given-names>
</name>
<name name-style="western">
<surname>Fang</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Garrison</surname>
<given-names>SJ</given-names>
</name>
<name name-style="western">
<surname>Kalla</surname>
<given-names>SE</given-names>
</name>
<name name-style="western">
<surname>Korniliev</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Kotlikoff</surname>
<given-names>MI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Complex disease and phenotype mapping in the domestic dog</article-title>
<source/>Nat Commun
          <year>2016</year>
<volume>7</volume>
<fpage>10460</fpage>
<pub-id pub-id-type="pmid">26795439</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yin</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Xiao</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Huang</surname>
<given-names>Z</given-names>
</name>
<name name-style="western">
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Zhou</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Han</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Tao</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Upregulation of liprin-α1 protein in the temporal neocortex of intractable epileptic patients and experimental rats</article-title>
<source/>Synapse
          <year>2011</year>
<volume>65</volume>
<fpage>742</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="pmid">21157931</pub-id>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Myers</surname>
<given-names>CT</given-names>
</name>
<name name-style="western">
<surname>McMahon</surname>
<given-names>JM</given-names>
</name>
<name name-style="western">
<surname>Schneider</surname>
<given-names>AL</given-names>
</name>
<name name-style="western">
<surname>Petrovski</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Allen</surname>
<given-names>AS</given-names>
</name>
<name name-style="western">
<surname>Carvill</surname>
<given-names>GL</given-names>
</name>
<name name-style="western">
<surname>Zemel</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Saykally</surname>
<given-names>JE</given-names>
</name>
<name name-style="western">
<surname>LaCroix</surname>
<given-names>AJ</given-names>
</name>
<name name-style="western">
<surname>Heinzen</surname>
<given-names>EL</given-names>
</name>
<name name-style="western">
<surname>Hollingsworth</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Nikanorova</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Corbett</surname>
<given-names>M</given-names>
</name>
<etal></etal>
<collab>Epi4K Consortium</collab>
</person-group>
<article-title>De Novo Mutations in SLC1A2 and CACNA1A Are Important Causes of Epileptic Encephalopathies</article-title>
<source/>Am J Hum Genet
          <year>2016</year>
<volume>99</volume>
<fpage>287</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="pmid">27476654</pub-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name name-style="western">
<surname>Santos</surname>
<given-names>RO</given-names>
</name>
</person-group>
<article-title>Investigating candidate genes in mesial temporal lobe epilepsy: PTPRM and IL1B genes</article-title>
<year>2015</year>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://repositorio.unicamp.br/bitstream/REPOSIP/312709/1/Santos_RenatoOliveirados_D.pdf">http://repositorio.unicamp.br/bitstream/REPOSIP/312709/1/Santos_RenatoOliveirados_D.pdf</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Haugarvoll</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Tzoulis</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Tran</surname>
<given-names>GT</given-names>
</name>
<name name-style="western">
<surname>Karlsen</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Engelsen</surname>
<given-names>BA</given-names>
</name>
<name name-style="western">
<surname>Knappskog</surname>
<given-names>PM</given-names>
</name>
<name name-style="western">
<surname>Bindoff</surname>
<given-names>LA</given-names>
</name>
</person-group>
<article-title>Myoclonus-dystonia and epilepsy in a family with a novel epsilon-sarcoglycan mutation</article-title>
<source/>J Neurol
          <year>2014</year>
<volume>261</volume>
<fpage>358</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="pmid">24297365</pub-id>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Schormair</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Kemlink</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Roeske</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Eckstein</surname>
<given-names>G</given-names>
</name>
<name name-style="western">
<surname>Xiong</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Lichtner</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Ripke</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Trenkwalder</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Zimprich</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Stiasny-Kolster</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Oertel</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Bachmann</surname>
<given-names>CG</given-names>
</name>
<name name-style="western">
<surname>Paulus</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome</article-title>
<source/>Nat Genet
          <year>2008</year>
<volume>40</volume>
<fpage>946</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">18660810</pub-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Davis</surname>
<given-names>LK</given-names>
</name>
<name name-style="western">
<surname>Meyer</surname>
<given-names>KJ</given-names>
</name>
<name name-style="western">
<surname>Rudd</surname>
<given-names>DS</given-names>
</name>
<name name-style="western">
<surname>Librant</surname>
<given-names>AL</given-names>
</name>
<name name-style="western">
<surname>Epping</surname>
<given-names>EA</given-names>
</name>
<name name-style="western">
<surname>Sheffield</surname>
<given-names>VC</given-names>
</name>
<name name-style="western">
<surname>Wassink</surname>
<given-names>TH</given-names>
</name>
</person-group>
<article-title>Novel copy number variants in children with autism and additional developmental anomalies</article-title>
<source/>J Neurodev Disord
          <year>2009</year>
<volume>1</volume>
<fpage>292</fpage>
<lpage>301</lpage>
<pub-id pub-id-type="pmid">21547721</pub-id>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ritz</surname>
<given-names>K</given-names>
</name>
<name name-style="western">
<surname>Gerrits</surname>
<given-names>MC</given-names>
</name>
<name name-style="western">
<surname>Foncke</surname>
<given-names>EM</given-names>
</name>
<name name-style="western">
<surname>van Ruissen</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>van der Linden</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Vergouwen</surname>
<given-names>MD</given-names>
</name>
<name name-style="western">
<surname>Bloem</surname>
<given-names>BR</given-names>
</name>
<name name-style="western">
<surname>Vandenberghe</surname>
<given-names>W</given-names>
</name>
<name name-style="western">
<surname>Crols</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Speelman</surname>
<given-names>JD</given-names>
</name>
<name name-style="western">
<surname>Baas</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Tijssen</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Myoclonus-dystonia: clinical and genetic evaluation of a large cohort</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2009</year>
<volume>80</volume>
<fpage>653</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">19066193</pub-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Bayat Mokhtari</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Homayouni</surname>
<given-names>TS</given-names>
</name>
<name name-style="western">
<surname>Baluch</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Morgatskaya</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Kumar</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Das</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>Yeger</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Combination therapy in combating cancer</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>38022</fpage>
<lpage>38043</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.16723">https://doi.org/10.18632/oncotarget.16723</ext-link>
</comment>
<pub-id pub-id-type="pmid">28410237</pub-id>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Croissant</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Estimation of multinomial logit models in R: The mlogit Packages</article-title>
<source/>R package version 02–2
          <year>2012</year>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/mlogit/mlogit.pdf">https://cran.r-project.org/web/packages/mlogit/mlogit.pdf</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Minassian</surname>
<given-names>BA</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>JR</given-names>
</name>
<name name-style="western">
<surname>Herbrick</surname>
<given-names>JA</given-names>
</name>
<name name-style="western">
<surname>Huizenga</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Soder</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Mungall</surname>
<given-names>AJ</given-names>
</name>
<name name-style="western">
<surname>Dunham</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Gardner</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Fong</surname>
<given-names>CY</given-names>
</name>
<name name-style="western">
<surname>Carpenter</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Jardim</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Satishchandra</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Andermann</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy</article-title>
<source/>Nat Genet
          <year>1998</year>
<volume>20</volume>
<fpage>171</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">9771710</pub-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Serratosa</surname>
<given-names>JM</given-names>
</name>
<name name-style="western">
<surname>Gómez-Garre</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Gallardo</surname>
<given-names>ME</given-names>
</name>
<name name-style="western">
<surname>Anta</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>de Bernabé</surname>
<given-names>DB</given-names>
</name>
<name name-style="western">
<surname>Lindhout</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Augustijn</surname>
<given-names>PB</given-names>
</name>
<name name-style="western">
<surname>Tassinari</surname>
<given-names>CA</given-names>
</name>
<name name-style="western">
<surname>Malafosse</surname>
<given-names>RM</given-names>
</name>
<name name-style="western">
<surname>Topcu</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Grid</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Dravet</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Berkovic</surname>
<given-names>SF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2)</article-title>
<source/>Hum Mol Genet
          <year>1999</year>
<volume>8</volume>
<fpage>345</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">9931343</pub-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Alonso</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Sasin</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Bottini</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Friedberg</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Friedberg</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Osterman</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Godzik</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Hunter</surname>
<given-names>T</given-names>
</name>
<name name-style="western">
<surname>Dixon</surname>
<given-names>J</given-names>
</name>
<name name-style="western">
<surname>Mustelin</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Protein tyrosine phosphatases in the human genome</article-title>
<source/>Cell
          <year>2004</year>
<volume>117</volume>
<fpage>699</fpage>
<lpage>711</lpage>
<pub-id pub-id-type="pmid">15186772</pub-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Navis</surname>
<given-names>AC</given-names>
</name>
<name name-style="western">
<surname>van den Eijnden</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Schepens</surname>
<given-names>JT</given-names>
</name>
<name name-style="western">
<surname>Hooft van Huijsduijnen</surname>
<given-names>R</given-names>
</name>
<name name-style="western">
<surname>Wesseling</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Hendriks</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>Protein tyrosine phosphatases in glioma biology</article-title>
<source/>Acta Neuropathol
          <year>2010</year>
<volume>119</volume>
<fpage>157</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="pmid">19936768</pub-id>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zondag</surname>
<given-names>GC</given-names>
</name>
<name name-style="western">
<surname>Reynolds</surname>
<given-names>AB</given-names>
</name>
<name name-style="western">
<surname>Moolenaar</surname>
<given-names>WH</given-names>
</name>
</person-group>
<article-title>Receptor protein-tyrosine phosphatase RPTPmu binds to and dephosphorylates the catenin p120(ctn)</article-title>
<source/>J Biol Chem
          <year>2000</year>
<volume>275</volume>
<fpage>11264</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">10753936</pub-id>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Burden-Gulley</surname>
<given-names>SM</given-names>
</name>
<name name-style="western">
<surname>Brady-Kalnay</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>PTPmu regulates N-cadherin-dependent neurite outgrowth</article-title>
<source/>J Cell Biol
          <year>1999</year>
<volume>144</volume>
<fpage>1323</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="pmid">10087273</pub-id>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ackley</surname>
<given-names>BD</given-names>
</name>
<name name-style="western">
<surname>Harrington</surname>
<given-names>RJ</given-names>
</name>
<name name-style="western">
<surname>Hudson</surname>
<given-names>ML</given-names>
</name>
<name name-style="western">
<surname>Williams</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Kenyon</surname>
<given-names>CJ</given-names>
</name>
<name name-style="western">
<surname>Chisholm</surname>
<given-names>AD</given-names>
</name>
<name name-style="western">
<surname>Jin</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>The two isoforms of the Caenorhabditis elegans leukocyte-common antigen related receptor tyrosine phosphatase PTP-3 function independently in axon guidance and synapse formation</article-title>
<source/>J Neurosci
          <year>2005</year>
<volume>25</volume>
<fpage>7517</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="pmid">16107639</pub-id>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Thwaites</surname>
<given-names>DT</given-names>
</name>
<name name-style="western">
<surname>Anderson</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>The SLC36 family of proton-coupled amino acid transporters and their potential role in drug transport</article-title>
<source/>Br J Pharmacol
          <year>2011</year>
<volume>164</volume>
<fpage>1802</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="pmid">21501141</pub-id>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Tani</surname>
<given-names>H</given-names>
</name>
<name name-style="western">
<surname>Bandrowski</surname>
<given-names>AE</given-names>
</name>
<name name-style="western">
<surname>Parada</surname>
<given-names>I</given-names>
</name>
<name name-style="western">
<surname>Wynn</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Huguenard</surname>
<given-names>JR</given-names>
</name>
<name name-style="western">
<surname>Prince</surname>
<given-names>DA</given-names>
</name>
<name name-style="western">
<surname>Reimer</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Modulation of epileptiform activity by glutamine and system A transport in a model of post-traumatic epilepsy</article-title>
<source/>Neurobiol Dis
          <year>2007</year>
<volume>25</volume>
<fpage>230</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">17070687</pub-id>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Dickens</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Webb</surname>
<given-names>SD</given-names>
</name>
<name name-style="western">
<surname>Antonyuk</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Giannoudis</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Owen</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Rädisch</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Hasnain</surname>
<given-names>SS</given-names>
</name>
<name name-style="western">
<surname>Pirmohamed</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Transport of gabapentin by LAT1 (SLC7A5)</article-title>
<source/>Biochem Pharmacol
          <year>2013</year>
<volume>85</volume>
<fpage>1672</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="pmid">23567998</pub-id>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zhu</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Dubey</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Bermudez</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Porter</surname>
<given-names>BE</given-names>
</name>
</person-group>
<article-title>Suppressing cAMP response element-binding protein transcription shortens the duration of status epilepticus and decreases the number of spontaneous seizures in the pilocarpine model of epilepsy</article-title>
<source/>Epilepsia
          <year>2015</year>
<volume>56</volume>
<fpage>1870</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">26419901</pub-id>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Tezenas du Montcel</surname>
<given-names>S</given-names>
</name>
<name name-style="western">
<surname>Clot</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Vidailhet</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Roze</surname>
<given-names>E</given-names>
</name>
<name name-style="western">
<surname>Damier</surname>
<given-names>P</given-names>
</name>
<name name-style="western">
<surname>Jedynak</surname>
<given-names>CP</given-names>
</name>
<name name-style="western">
<surname>Camuzat</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Lagueny</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Vercueil</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Doummar</surname>
<given-names>D</given-names>
</name>
<name name-style="western">
<surname>Guyant-Maréchal</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Houeto</surname>
<given-names>JL</given-names>
</name>
<name name-style="western">
<surname>Ponsot</surname>
<given-names>G</given-names>
</name>
<etal></etal>
<collab>French Dystonia Network</collab>
</person-group>
<article-title>Epsilon sarcoglycan mutations and phenotype in French patients with myoclonic syndromes</article-title>
<source/>J Med Genet
          <year>2006</year>
<volume>43</volume>
<fpage>394</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="pmid">16227522</pub-id>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name name-style="western">
<surname>Xie</surname>
<given-names>N</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Ge</surname>
<given-names>X</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Role of the Mitochondrial Calcium Uniporter in Rat Hippocampal Neuronal Death After Pilocarpine-Induced Status Epilepticus</article-title>
<source/>Neurochem Res
          <year>2015</year>
<volume>40</volume>
<fpage>1739</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="pmid">26148531</pub-id>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Acharya</surname>
<given-names>MM</given-names>
</name>
<name name-style="western">
<surname>Katyare</surname>
<given-names>SS</given-names>
</name>
</person-group>
<article-title>Structural and functional alterations in mitochondrial membrane in picrotoxin-induced epileptic rat brain</article-title>
<source/>Exp Neurol
          <year>2005</year>
<volume>192</volume>
<fpage>79</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="pmid">15698621</pub-id>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Chuang</surname>
<given-names>YC</given-names>
</name>
<name name-style="western">
<surname>Chang</surname>
<given-names>AY</given-names>
</name>
<name name-style="western">
<surname>Lin</surname>
<given-names>JW</given-names>
</name>
<name name-style="western">
<surname>Hsu</surname>
<given-names>SP</given-names>
</name>
<name name-style="western">
<surname>Chan</surname>
<given-names>SH</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction and ultrastructural damage in the hippocampus during kainic acid-induced status epilepticus in the rat</article-title>
<source/>Epilepsia
          <year>2004</year>
<volume>45</volume>
<fpage>1202</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">15461674</pub-id>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Baughman</surname>
<given-names>JM</given-names>
</name>
<name name-style="western">
<surname>Perocchi</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Girgis</surname>
<given-names>HS</given-names>
</name>
<name name-style="western">
<surname>Plovanich</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Belcher-Timme</surname>
<given-names>CA</given-names>
</name>
<name name-style="western">
<surname>Sancak</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Bao</surname>
<given-names>XR</given-names>
</name>
<name name-style="western">
<surname>Strittmatter</surname>
<given-names>L</given-names>
</name>
<name name-style="western">
<surname>Goldberger</surname>
<given-names>O</given-names>
</name>
<name name-style="western">
<surname>Bogorad</surname>
<given-names>RL</given-names>
</name>
<name name-style="western">
<surname>Koteliansky</surname>
<given-names>V</given-names>
</name>
<name name-style="western">
<surname>Mootha</surname>
<given-names>VK</given-names>
</name>
</person-group>
<article-title>Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter</article-title>
<source/>Nature
          <year>2011</year>
<volume>476</volume>
<fpage>341</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">21685886</pub-id>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Leiserson</surname>
<given-names>MD</given-names>
</name>
<name name-style="western">
<surname>Vandin</surname>
<given-names>F</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>HT</given-names>
</name>
<name name-style="western">
<surname>Dobson</surname>
<given-names>JR</given-names>
</name>
<name name-style="western">
<surname>Eldridge</surname>
<given-names>JV</given-names>
</name>
<name name-style="western">
<surname>Thomas</surname>
<given-names>JL</given-names>
</name>
<name name-style="western">
<surname>Papoutsaki</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<name name-style="western">
<surname>Niu</surname>
<given-names>B</given-names>
</name>
<name name-style="western">
<surname>McLellan</surname>
<given-names>M</given-names>
</name>
<name name-style="western">
<surname>Lawrence</surname>
<given-names>MS</given-names>
</name>
<name name-style="western">
<surname>Gonzalez-Perez</surname>
<given-names>A</given-names>
</name>
<name name-style="western">
<surname>Tamborero</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes</article-title>
<source/>Nat Genet
          <year>2015</year>
<volume>47</volume>
<fpage>106</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">25501392</pub-id>
</element-citation>
</ref>
<ref id="R54">
<label>54</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name name-style="western">
<surname>Franceschini</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>STRINGdb Package Vignette</article-title>
<year>2015</year>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://www.bioconductor.org/packages/3.0/bioc/vignettes/STRINGdb/inst/doc/STRINGdb.pdf">http://www.bioconductor.org/packages/3.0/bioc/vignettes/STRINGdb/inst/doc/STRINGdb.pdf</ext-link>
</comment>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>